MYOM2 and Miyoshi myopathy: Response evaluation in MM has been based on the assessment of serum M protein and serum free light chain (sFLC) values as surrogates for tumor burden as well as bone marrow (BM) plasma-cell quantitation from BM marrow aspirates [4].